141 related articles for article (PubMed ID: 34952136)
21. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
22. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Int J Pharm; 2024 Jan; 650():123708. PubMed ID: 38135258
[TBL] [Abstract][Full Text] [Related]
23. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
Wang J; Bruin MAC; Gan C; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Pharm; 2020 May; 581():119277. PubMed ID: 32234426
[TBL] [Abstract][Full Text] [Related]
24. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
[TBL] [Abstract][Full Text] [Related]
25. Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.
Li W; Sparidans RW; Wang Y; Martins MLF; de Waart DR; van Tellingen O; Song JY; Lebre MC; van Hoppe S; Wagenaar E; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116644. PubMed ID: 38692057
[TBL] [Abstract][Full Text] [Related]
26. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
[TBL] [Abstract][Full Text] [Related]
27. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
Martínez-Chávez A; Broeders J; Lebre MC; Tibben MT; Rosing H; Beijnen JH; Schinkel AH
Eur J Pharm Sci; 2021 Apr; 159():105740. PubMed ID: 33524505
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of the KRAS
Loos NHC; Retmana IA; Rijmers J; Wang Y; Gan C; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2023 Oct; 166():115304. PubMed ID: 37586117
[TBL] [Abstract][Full Text] [Related]
29. Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.
F Martins ML; Heydari P; Li W; Martínez-Chávez A; Venekamp N; Lebre MC; Lucas L; Beijnen JH; Schinkel AH
Front Pharmacol; 2022; 13():855000. PubMed ID: 35308219
[TBL] [Abstract][Full Text] [Related]
30. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
31. Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.
Loos NHC; Ferreira Martins ML; Rijmers J; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2024 Apr; 21(4):1952-1964. PubMed ID: 38423793
[TBL] [Abstract][Full Text] [Related]
32. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Tang SC; Kort A; Cheung KL; Rosing H; Fukami T; Durmus S; Wagenaar E; Hendrikx JJ; Nakajima M; van Vlijmen BJ; Beijnen JH; Schinkel AH
Mol Pharm; 2015 Oct; 12(10):3714-23. PubMed ID: 26317243
[TBL] [Abstract][Full Text] [Related]
33. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.
Sane R; Agarwal S; Elmquist WF
Drug Metab Dispos; 2012 Aug; 40(8):1612-9. PubMed ID: 22611067
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
[TBL] [Abstract][Full Text] [Related]
35. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
37. ABCB1 attenuates brain exposure to the KRAS
Rijmers J; Retmana IA; Bui V; Arguedas D; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2024 Jun; 175():116720. PubMed ID: 38733773
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
[TBL] [Abstract][Full Text] [Related]
39. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Sane R; Mittapalli RK; Elmquist WF
J Pharm Sci; 2013 Apr; 102(4):1343-54. PubMed ID: 23334925
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
